Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
AnGes Alters Strategy for Collategene, Halts Japan Sales for Fresh Submission
AnGes is changing its development strategy for its HGF gene therapy Collategene (beperminogene perplasmid). The change involves the pulling of its Japanese application currently under review that seeks a conversion from conditional to full approval, which will then be followed…
To read the full story
Related Article
- FIRM Warns Conditional Approval Pricing Change Could Chill Regenerative Medicine R&D
February 3, 2026
- Japan Sets New Pricing Rules for Conditionally Approved Regenerative Medicines, Starting with Elevidys
January 15, 2026
- Chuikyo Backs Halving Profit Coefficient for Conditionally Approved Regenerative Medicines
November 13, 2025
- Chuikyo Urges Stricter Pricing Rules for Conditionally Approved Regenerative Medicines
October 16, 2025
- Chuikyo Agrees to Vet Conditional Scheme for Regenerative Medicine as Elevidys Gets Approval
May 15, 2025
- Mitsubishi Walks Away from Collategene Deal with AnGes
August 26, 2024
- Chuikyo Urges Rethink of Health Coverage for Conditionally Approved Regenerative Medicines
August 9, 2024
- HeartSheet’s Conditional Approval to Be Withdrawn as Early as August
July 26, 2024
- Payer Chides AnGes’s Course Change on Collategene, Urges Re-Think of System’s Set-Up
July 4, 2024
- AnGes Seeks Full Approval for Gene Therapy Collategene in Japan
June 1, 2023
- AnGes Calls off Japan Development of Collategene for Additional Indication
September 8, 2022
- Collategene Generates Only 4 Million Yen in 4 Months
February 5, 2020
- Full Approval in Japan Will Be 1st Goal for Collategene: AnGes Chief
September 11, 2019
- Anges, Mitsubishi Tanabe to Launch Gene Therapy Collategene on Sept. 10
September 5, 2019
- Gene Therapy Collategene Gets 600,000 Yen Price Tag, Peak Sales Put at 1.2 Billion Yen
August 28, 2019
- After Listing Delayed, Collategene Expected to Reach Market by Year-End: AnGes Founder
July 22, 2019
- AnGes Delays Launch of Collategene, “Sale Preparations Will Take More Time”
May 15, 2019
- AnGes Bags Conditional Approval for Collategene Gene Therapy
March 27, 2019
- MHLW Panel OKs AnGes’ Gene Therapy Collategene for Conditional Approval
February 21, 2019
BUSINESS
- Bayer Detects Nitrosamine in Contrast Agent, Restricts Shipments
April 27, 2026
- Chugai to Launch 3 Global PIIIs of Bispecific Antibody NXT007 in 2026
April 27, 2026
- Astellas Bags US$75 Million from MSN after Myrbetriq Patent Settlement
April 27, 2026
- Kura, Kyowa Kirin Start Japan PII Trial of Ziftomenib for AML Filing
April 27, 2026
- Pharma Earnings Season Kicks Off; Off-Year Impact, Overseas Trends in Focus
April 24, 2026
AAV (adeno-associated virus) gene therapies are moving beyond rare diseases into more prevalent conditions, with neovascular, or wet, age-related macular…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…